These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin. Tao S; Otomo K; Ono Y; Osaka Y; Hirao T; Koura K; Manno T; Ueshima D; Shimizu S; Isobe M; Hirao K J Interv Card Electrophysiol; 2017 Mar; 48(2):167-175. PubMed ID: 27943112 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196 [TBL] [Abstract][Full Text] [Related]
9. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Naccarelli GV; Cappato R; Hohnloser SH; Marchlinski FE; Wilber DJ; Xiang J; Ma C; Hess S; Davies DW; Fields LE; Natale A; J Interv Card Electrophysiol; 2014 Nov; 41(2):107-16. PubMed ID: 25005452 [TBL] [Abstract][Full Text] [Related]
10. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868 [TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation. Kawabata M; Sasaki T; Maeda S; Shirai Y; Yamauchi Y; Nitta J; Goya M; Hirao K Int Heart J; 2016 Dec; 57(6):712-716. PubMed ID: 27818480 [TBL] [Abstract][Full Text] [Related]
12. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Yadlapati A; Groh C; Passman R Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087 [TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362 [TBL] [Abstract][Full Text] [Related]